Palvella Therapeutics, Inc. (PVLA): who owns it and who trades it
As of Nov 16, 2026, PVLA insiders reported 76 open-market sales worth $15.9M and 3 purchases worth $850K in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was George M Jenkins (Director), with $7.7M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Palvella Therapeutics
From the latest filingsOverall: more selling than buying. Famous investors mostly sold. Insiders mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, PVLA insiders reported $850K of open-market purchases and $15.9M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | Jeffrey S Martini | Chief Scientific Officer | Sale plan | 1,650 | $164.14 | $271K | Form 4 |
| Nov 11, 2026 | Jeffrey S Martini | Chief Scientific Officer | Sale plan | 1,467 | $165.78 | $243K | Form 4 |
| Nov 11, 2026 | Jeffrey S Martini | Chief Scientific Officer | Sale plan | 1,133 | $166.76 | $189K | Form 4 |
| Nov 11, 2026 | Jeffrey S Martini | Chief Scientific Officer | Sale plan | 1,200 | $167.75 | $201K | Form 4 |
| Nov 11, 2026 | Jeffrey S Martini | Chief Scientific Officer | Sale plan | 600 | $168.73 | $101K | Form 4 |
| Nov 11, 2026 | Jeffrey S Martini | Chief Scientific Officer | Sale plan | 200 | $169.78 | $34K | Form 4 |
| Nov 10, 2026 | Jeffrey S Martini | Chief Scientific Officer | Sale plan | 100 | $163.34 | $16.3K | Form 4 |
| Nov 10, 2026 | Jeffrey S Martini | Chief Scientific Officer | Sale plan | 1,449 | $164.85 | $239K | Form 4 |
| Nov 10, 2026 | Jeffrey S Martini | Chief Scientific Officer | Sale plan | 1,651 | $165.85 | $274K | Form 4 |
| Nov 10, 2026 | Jeffrey S Martini | Chief Scientific Officer | Sale plan | 1,500 | $166.91 | $250K | Form 4 |
| Nov 10, 2026 | Jeffrey S Martini | Chief Scientific Officer | Sale plan | 200 | $167.81 | $33.6K | Form 4 |
| Nov 10, 2026 | Jeffrey S Martini | Chief Scientific Officer | Sale plan | 550 | $169.03 | $93K | Form 4 |
| Nov 10, 2026 | Jeffrey S Martini | Chief Scientific Officer | Sale plan | 800 | $172.12 | $138K | Form 4 |
| Oct 21, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 2,043 | $123.62 | $253K | Form 4 |
| Oct 21, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 1,663 | $125.16 | $208K | Form 4 |
| Oct 21, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 607 | $126.19 | $76.6K | Form 4 |
| Oct 14, 2026 | George M Jenkins | Director | Sale plan | 476 | $121.14 | $57.7K | Form 4 |
| Oct 14, 2026 | George M Jenkins | Director | Sale plan | 2,072 | $122.62 | $254K | Form 4 |
| Oct 14, 2026 | George M Jenkins | Director | Sale plan | 2,604 | $123.29 | $321K | Form 4 |
| Oct 14, 2026 | George M Jenkins | Director | Sale plan | 920 | $124.37 | $114K | Form 4 |
| Oct 14, 2026 | George M Jenkins | Director | Sale plan | 597 | $125.33 | $74.8K | Form 4 |
| Oct 14, 2026 | George M Jenkins | Director | Sale plan | 505 | $126.55 | $63.9K | Form 4 |
| Oct 13, 2026 | George M Jenkins | Director | Sale plan | 2,004 | $128.52 | $258K | Form 4 |
| Oct 13, 2026 | George M Jenkins | Director | Sale plan | 1,644 | $129.23 | $212K | Form 4 |
| Oct 13, 2026 | George M Jenkins | Director | Sale plan | 990 | $130.48 | $129K | Form 4 |
| Oct 13, 2026 | George M Jenkins | Director | Sale plan | 1,035 | $131.49 | $136K | Form 4 |
| Oct 13, 2026 | George M Jenkins | Director | Sale plan | 579 | $132.40 | $76.7K | Form 4 |
| Oct 13, 2026 | George M Jenkins | Director | Sale plan | 922 | $133.72 | $123K | Form 4 |
| Oct 12, 2026 | George M Jenkins | Director | Sale plan | 5,095 | $132.62 | $676K | Form 4 |
| Oct 12, 2026 | George M Jenkins | Director | Sale plan | 2,458 | $133.25 | $328K | Form 4 |
| Oct 12, 2026 | George M Jenkins | Director | Sale plan | 3,335 | $134.21 | $448K | Form 4 |
| Oct 12, 2026 | George M Jenkins | Director | Sale plan | 1,447 | $135.50 | $196K | Form 4 |
| Oct 12, 2026 | George M Jenkins | Director | Sale plan | 817 | $136.44 | $111K | Form 4 |
| Sep 16, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 1,654 | $153.24 | $253K | Form 4 |
| Sep 16, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 989 | $152.36 | $151K | Form 4 |
| Sep 16, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 1,659 | $151.16 | $251K | Form 4 |
| Sep 15, 2026 | George M Jenkins | Director | Sale plan | 560 | $151.33 | $84.7K | Form 4 |
| Sep 15, 2026 | George M Jenkins | Director | Sale plan | 954 | $149.38 | $143K | Form 4 |
| Sep 15, 2026 | George M Jenkins | Director | Sale plan | 263 | $150.40 | $39.6K | Form 4 |
| Sep 14, 2026 | George M Jenkins | Director | Sale plan | 5,632 | $151.46 | $853K | Form 4 |
| Sep 14, 2026 | George M Jenkins | Director | Sale plan | 6,160 | $152.12 | $937K | Form 4 |
| Sep 14, 2026 | George M Jenkins | Director | Sale plan | 1,560 | $153.10 | $239K | Form 4 |
| Sep 11, 2026 | George M Jenkins | Director | Sale plan | 1,274 | $153.06 | $195K | Form 4 |
| Sep 11, 2026 | George M Jenkins | Director | Sale plan | 4,577 | $151.72 | $694K | Form 4 |
| Sep 11, 2026 | George M Jenkins | Director | Sale plan | 6,520 | $150.62 | $982K | Form 4 |
| Sep 2, 2026 | Christopher P Kiritsy | Director | Sale | 313 | $157.00 | $49.1K | Form 4 |
| Aug 19, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 102 | $155.59 | $15.9K | Form 4 |
| Aug 19, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 400 | $153.00 | $61.2K | Form 4 |
| Aug 19, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 1,998 | $151.80 | $303K | Form 4 |
| Aug 19, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 1,500 | $151.39 | $227K | Form 4 |
| Aug 19, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 302 | $156.77 | $47.3K | Form 4 |
| Jul 15, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 1,911 | $150.25 | $287K | Form 4 |
| Jul 15, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 1,029 | $149.27 | $154K | Form 4 |
| Jul 15, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 840 | $148.40 | $125K | Form 4 |
| Jul 15, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 522 | $147.14 | $76.8K | Form 4 |
| Jun 17, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 25 | $112.23 | $2.8K | Form 4 |
| Jun 17, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 2,390 | $110.26 | $264K | Form 4 |
| Jun 17, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 1,887 | $111.31 | $210K | Form 4 |
| May 20, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 48 | $111.90 | $5.4K | Form 4 |
| May 20, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 3,363 | $110.35 | $371K | Form 4 |
| May 20, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 891 | $111.30 | $99.2K | Form 4 |
| Apr 15, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 100 | $130.33 | $13K | Form 4 |
| Apr 15, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 639 | $129.17 | $82.5K | Form 4 |
| Apr 15, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 561 | $128.23 | $71.9K | Form 4 |
| Apr 15, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 1,500 | $127.13 | $191K | Form 4 |
| Apr 15, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 1,502 | $125.96 | $189K | Form 4 |
| Mar 30, 2026 | George M Jenkins | Director | Purchase | 445 | $112.30 | $50K | Form 4 |
| Mar 18, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 2,268 | $117.56 | $267K | Form 4 |
| Mar 18, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 1,730 | $118.37 | $205K | Form 4 |
| Mar 18, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 304 | $119.08 | $36.2K | Form 4 |
| Feb 27, 2026 | George M Jenkins | Director | Purchase | 4,000 | $125.00 | $500K | Form 4 |
| Feb 27, 2026 | Elaine J Heron | Director | Purchase | 2,400 | $125.00 | $300K | Form 4 |
| Feb 18, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 3,026 | $79.16 | $240K | Form 4 |
| Feb 18, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 1,276 | $79.97 | $102K | Form 4 |
| Jan 21, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 3,749 | $97.94 | $367K | Form 4 |
| Jan 21, 2026 | Kathleen Goin | Chief Operating Officer | Sale plan | 553 | $95.49 | $52.8K | Form 4 |
| Dec 17, 2025 | Kathleen Goin | Chief Operating Officer | Sale plan | 4,302 | $96.47 | $415K | Form 4 |
| Nov 19, 2025 | Kathleen Goin | Chief Operating Officer | Sale plan | 2,802 | $86.51 | $242K | Form 4 |
| Nov 19, 2025 | Kathleen Goin | Chief Operating Officer | Sale plan | 1,500 | $85.72 | $129K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| George M Jenkins | Director | $550K | $7.7M | Oct 14, 2026 |
| Kathleen Goin | Chief Operating Officer | – | $6M | Oct 21, 2026 |
| Jeffrey S Martini | Chief Scientific Officer | – | $2.1M | Nov 11, 2026 |
| Elaine J Heron | Director | $300K | – | Feb 27, 2026 |
| Christopher P Kiritsy | Director | – | $49.1K | Sep 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
PVLA short interest
High short interest. 18.1% of PVLA shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 21%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.60M PVLA shares were sold short, 18.1% of the shares outstanding, up 8.1% from the report before. At the average daily volume of 226,984 shares, buying them all back would take about 11.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.60M | 18.06% | +8% | 226,984 | 11.5 |
| Oct 15, 2026 | 2.41M | 16.71% | -5% | 244,860 | 9.8 |
| Sep 30, 2026 | 2.52M | 17.52% | +9% | 236,256 | 10.7 |
| Sep 15, 2026 | 2.33M | 16.14% | +2% | 181,436 | 12.8 |
| Aug 31, 2026 | 2.29M | 15.90% | +7% | 205,613 | 11.1 |
| Aug 14, 2026 | 2.15M | 14.92% | +4% | 167,918 | 12.8 |
| Jul 31, 2026 | 2.07M | 14.35% | -5% | 224,496 | 9.2 |
| Jul 15, 2026 | 2.18M | 15.21% | -8% | 237,913 | 9.2 |
| Jun 30, 2026 | 2.37M | 16.53% | +14% | 374,785 | 6.3 |
| Jun 15, 2026 | 2.08M | 14.51% | -2% | 317,852 | 6.5 |
| May 29, 2026 | 2.12M | 14.80% | -1% | 171,805 | 12.3 |
| May 15, 2026 | 2.15M | 15.01% | -1% | 242,147 | 8.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Palvella Therapeutics company events
Palvella Therapeutics filed 20 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 28, 2026AnnouncementPalvella Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has accepted for filing and granted Priority Review to the Company’s New Drug Application for QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations. Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- Jul 14, 2026AnnouncementPalvella Therapeutics, Inc. posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time. Filing
- Jun 30, 2026LeadershipThe Board of Directors of Palvella Therapeutics, Inc. increased the size of the Board from seven to eight members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed Matthew Pauls, to serve as a Class I director, with an initial term expiring at the Company’s… Filing
- Jun 16, 2026LeadershipAt the 2026 Annual Meeting of Stockholders of Palvella Therapeutics, Inc., the Company’s stockholders approved the amendment to the Palvella Therapeutics, Inc. 2024 Equity Incentive Plan to increase the authorized shares issuable thereunder by 750,000 shares. Filing
- May 20, 2026AnnouncementPalvella Therapeutics, Inc. issued a press release announcing that new positive clinical data and findings from the Company’s Phase 3 SELVA and Phase 2 TOIVA studies were reported at the International Society for the Study of Vascular Anomalies World Congress 2026. Filing
- May 15, 2026AnnouncementPalvella Therapeutics, Inc. issued a press release announcing that new data from the Company’s Phase 2 TOIVA trial of QTORIN™ rapamycin in patients with cutaneous venous malformations were presented at the 83rd Annual Meeting of the Society for Investigative Dermatology. Filing
- May 13, 2026AnnouncementPalvella Therapeutics, Inc. received approval from the Nasdaq Listing Qualifications Department to move the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Market, effective with the open of business on May 13, 2026. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 13, 2026LeadershipThe Board of Directors of Palvella Therapeutics, Inc. increased the size of the Board from six to seven members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed John Doux, M.D., to serve as a Class III director, with an initial term expiring at the Company’s… Filing
- Apr 7, 2026AnnouncementPalvella Therapeutics, Inc. posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time. Filing
- Mar 31, 2026ResultsReleased financial results. Filing
- Feb 26, 2026AgreementPalvella Therapeutics, Inc. entered into an underwriting agreement with TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated, as representatives of the underwriters listed in Schedule A thereto, pursuant to which the Company agreed to issue and sell an… Filing
- Feb 24, 2026ResultsReleased financial results. Filing
- Feb 24, 2026AnnouncementShared information with investors. Filing
- Feb 24, 2026AnnouncementPalvella Therapeutics, Inc. issued a press release announcing positive topline results from the Company’s Phase 3 SELVA study of QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations. Filing
- Jan 29, 2026AnnouncementPalvella Therapeutics, Inc. posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time. Filing
- Jan 12, 2026AnnouncementPalvella Therapeutics, Inc. posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time. Filing
- Dec 15, 2025AnnouncementThe Company issued a press release announcing positive topline results from the Company’s ongoing Phase 2 TOIVA study of QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of cutaneous venous malformations. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Palvella Therapeutics financials
Famous investors that hold PVLA
2 of the 50 well-known investors we track reported holding PVLA in their latest 13F filing. The largest position is Jim Simons's, worth $5.1M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 37,270 | $5.1M | 0.0% | -30% |
| Israel Englander · Millennium Management | Q3 2026 | 19,147 | $2.6M | 0.0% | -63% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named PVLA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Frazier Life Sciences Public Fund, L.P. | 13G/A | 5.9% |
| Nov 16, 2026 | Frazier Life Sciences Public Fund, L.P. | 13G/A | 5.9% |
| Oct 28, 2026 | Jennison Associates LLC | 13G/A | 7.7% |
| Oct 28, 2026 | Jennison Associates LLC | 13G/A | 7.7% |
Questions about Palvella Therapeutics, Inc. (PVLA) stock
Are PVLA insiders buying or selling?
In the last 12 months, PVLA insiders reported 3 open-market purchases worth $850K and 76 sales worth $15.9M. The latest trade was on Nov 11, 2026. See every trade.
What is the short interest in PVLA?
As of Oct 30, 2026, 2.60M PVLA shares were sold short, 18.1% of the shares outstanding, up 8.1% from the report before. At the average daily volume of 226,984 shares, buying them all back would take about 11.5 trading days (days to cover). See the history.
Which famous investors hold PVLA?
2 of the 50 well-known investors we track reported PVLA in their latest 13F filing, including Jim Simons, Israel Englander. The largest position is worth $5.1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.